Injectable Drug Delivery Devices Market size was over USD 115.03 billion in 2023 and is anticipated to reach USD 280.59 billion by the end of 2036, growing at around 7.1% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of injectable drug delivery devices is assessed at USD 121.56 billion.
The growth of the global injectable drug delivery device market can be attributed to the increasing implementation of biologics, growing prevalence of chronic disorders, escalating incidence of needlestick injuries, and other benefits of injections. Factors such as safety syringes, prefilled syringes, auto-injectors, and others, have increased the demand for injectable drug delivery devices. Moreover, increasing prevalence of chronic diseases, such as, cardiovascular disease, cancer, auto-immune disease and diabetes, is expected to drive the demand for such devices. According to the report by the WHO, 422 million people have diabetes on a global level, and 1.6 million deaths are directly attributed to diabetes each year. Moreover, Cardiovascular diseases (CVD) are currently the leading cause of deaths and disability worldwide causing around 17.9 million deaths globally. The need for self-injections in homecare settings without the requirement of any professional help for the treatment of these diseases is estimated to act as a major growth driver for the market.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
7.1% |
|
Base Year Market Size (2023) |
USD 115.03 billion |
|
Forecast Year Market Size (2036) |
USD 280.59 billion |
|
Regional Scope |
|
The global injectable drug delivery devices market is segmented on the basis of product into conventional injection devices, and advanced injection devices, out of which, the advanced injection devices segment is expected to grab the largest market share in the forecast period, on the back of its advantages, such as, convenient application and low healthcare cost.
Based on end-user, the hospital & clinics segment is expected to gain largest share in terms of revenue, on the back of increasing patient influx and longer stay of the patients at the hospitals suffering from chronic diseases.
|
By Product |
|
|
By Therapeutic Area |
|
|
By Route of Delivery
|
|
|
By End User
|
|
Geographically, the market is segmented into North America, Latin America, Europe, Asia Pacific and the Middle East & Africa region. Asia Pacific industry is poised to hold largest revenue share by 2036, propelled by increasing incidence of chronic disorders in the region. Additionally, the increasing healthcare expenditure and growing development of advanced injectable devices for drug delivery in the region are expected to drive the market growth.
North America Market Analysis
Furthermore, in 2036, the market in the North America region is expected to hold the most significant share in the global injectable drug delivery market, on the back of a higher rate of implementation of innovative injectable drug delivery devices for the treatment of various diseases, such as, diabetes mellitus, autoimmune disorders, cancers, and others. Additionally, the rising prevalence of cancer cases and diabetes in the United States is expected to promote the growth of the North America injectable drug delivery market.
January 2021: Novo Nordisk A/S, announced the approval from the US Food and Drug Administration for semaglutide, which is an injectable treatment for chronic weight management in adults such as high blood pressure, high cholesterol, and others.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?